Overview

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Trovax and GM-CSF in patients with prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute
The Methodist Hospital System
Collaborator:
Oxford BioMedica
Treatments:
Sargramostim